Koers Juva Life Inc. Other OTC
Aandelen
JUVAF
CA48222R1010
Farmaceutische producten
Omzet 2021 | 3,87 3,62 | Omzet 2022 | 5,76 5,39 | Marktkapitalisatie | 10,4 mln. 9,73 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -11 mln. -10,29 mln. | Nettowinst (verlies) 2022 | -10 mln. -9,35 mln. | EV/omzet 2021 | 8.085.207 x |
Nettoschuld 2021 | 1,62 mln. 1,52 mln. | Nettoschuld 2022 | 7,38 mln. 6,9 mln. | EV/omzet 2022 | 3.084.662 x |
K/w-verhouding 2021 |
-2,51
x | K/w-verhouding 2022 |
-0,99
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 52,48% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Douglas Chloupek
CEO | Chief Executive Officer | - | - |
Mathew Lee
DFI | Director of Finance/CFO | 40 | 03-04-19 |
Dan Hughes
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kari A. Gothie
ADM | Chief Administrative Officer | - | 30-05-19 |
Mathew Lee
DFI | Director of Finance/CFO | 40 | 03-04-19 |
Douglas Chloupek
CEO | Chief Executive Officer | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,05% | 3,66 mld. | |
+109,78% | 2 mld. | |
+87,30% | 61,69 mln. |